Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High?Zacks Investment Research • 04/29/26
Amneal Pharmaceuticals (AMRX) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research • 04/29/26
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?Zacks Investment Research • 04/29/26
AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary ResultsZacks Investment Research • 04/23/26
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 04/23/26
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass EstimatesZacks Investment Research • 04/22/26
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar LeaderBusiness Wire • 04/22/26
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone GuidanceGlobeNewsWire • 04/22/26
Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside PotentialSeeking Alpha • 04/21/26
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson's Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®GlobeNewsWire • 04/20/26
Amneal shares rise after UBS initiates at Buy, cites “best-in-group” growth in specialty pharmaProactive Investors • 04/17/26
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.GlobeNewsWire • 04/14/26
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson's Awareness MonthGlobeNewsWire • 04/07/26
Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A BuySeeking Alpha • 03/16/26